Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: Investigating the behavioural and biochemical changes

Brain Research

Volumn 1412, Issue , 2011, Pages 28-36

  Daya, Ritesh P ^a   Tan, Mattea L ^a   Sookram, Christal D ^a   Skoblenick, Kevin ^a,b   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Alpha phenyl N tert butylnitrone; Apoptosis inducing factor; Behavioural supersensitivity; Free radicals; Haloperidol; Oxidative stress

Indexed keywords

APOPTOSIS INDUCING FACTOR; FREE RADICAL; HALOPERIDOL; MESSENGER RNA; N TERT BUTYL ALPHA PHENYLNITRONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; LIPID PEROXIDATION; MALE; MASTICATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SUPERSENSITIVITY; TARDIVE DYSKINESIA;

ANIMALS; CATALASE; CORPUS STRIATUM; CYCLIC N-OXIDES; DYSKINESIA, DRUG-INDUCED; GLUTATHIONE; HALOPERIDOL; LIPID PEROXIDATION; MALE; MOTOR ACTIVITY; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SUPEROXIDE DISMUTASE;

ANIMALIA; RATTUS;

EID: 80052033813     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.07.014     Document Type: Article

References (62)

1. O.A. Andreassen, T.O. Aamo, and H.A. Joorgensen Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats Br. J. Pharmacol. 119 1996 751 757 (Pubitemid 26356589)
2. O.A. Andreassen, and H.A. Jorgensen Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol. 61 2000 525 541 (Pubitemid 30169057)
3. Y. Barak, E. Shamir, H. Zemishlani, I. Mirecki, P. Toren, and R. Weizman Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 1199 1202 (Pubitemid 35256116)
4. C. Beauchamp, and I. Fridovich Superoxide dismutase: improved assays and an assay applicable to acrylamide gels Anal. Biochem. 44 1971 276 287
5. R.F. Beers Jr., and I.W. Sizer A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase J. Biol. Chem. 195 1952 133 140
6. C. Behl, F. Lezoulac'h, M. Widmann, R. Rupprecht, and F. Holsboer Oxidative stress-resistant cells are protected against haloperidol toxicity Brain Res. 717 1996 193 195 (Pubitemid 26153452)
7. M. Bishnoi, K. Chopra, and S.K. Kulkarni Protective effect of curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain Pharmacol. Biochem. Behav. 88 2008 511 522 (Pubitemid 350266795)
8. J.S. Braun, R. Novak, P.J. Murray, C.M. Eischen, S.A. Susin, G. Kroemer, A. Halle, J.R. Weber, E.I. Tuomanen, and J.L. Cleveland Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus J. Infect. Dis. 184 2001 1300 1309 (Pubitemid 33055575)
9. J.L. Cadet, and L.A. Kahler Free radical mechanisms in schizophrenia and tardive dyskinesia Neurosci. Biobehav. Rev. 18 1994 457 467
10. J.L. Cadet, and J.B. Lohr Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E Ann. N. Y. Acad. Sci. 570 1989 176 185 (Pubitemid 20103394)
11. J.J. Canales, G. Gilmour, and S.D. Iversen The role of nigral and thalamic output pathways in the expression of oral stereotypies induced by amphetamine injections into the striatum Brain Res. 856 2000 176 183 (Pubitemid 30085524)
12. X. Cao, and J.W. Phillis The free radical scavenger, alpha-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils Free Radic. Res. 23 1995 365 370
13. J.M. Carney, P.E. Starke-Reed, C.N. Oliver, R.W. Landum, M.S. Cheng, J.F. Wu, and R.A. Floyd Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha- phenylnitrone Proc. Natl. Acad. Sci. U.S.A. 88 1991 3633 3636 (Pubitemid 21916677)
14. D.E. Casey Tardive dyskinesia: pathophysiology and animal models J. Clin. Psychiatry 61 Suppl 4 2000 5 9 (Pubitemid 30158596)
15. S. Chiu, and R.K. Mishra Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide Eur. J. Pharmacol. 53 1979 119 125 (Pubitemid 9201270)
16. V.Z. Chong, L.T. Young, and R.K. Mishra cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment J. Neurochem. 82 2002 1533 1539
17. M. Diana, M. Collu, A. Mura, and G.L. Gessa Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine Eur. J. Pharmacol. 211 1992 415 419
18. A.M. Elkashef, and R.J. Wyatt Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E Schizophr. Bull. 25 1999 731 740 (Pubitemid 30013555)
19. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
20. J. Fang, G. McKay, J.X. Song, A. Remillrd, X.M. Li, and K. Midha In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes Drug Metab. Dispos. 29 2001 1638 1643 (Pubitemid 33111597)
21. S. Fleminger, N.M.J. Rupniak, M.D. Hall, P. Jenner, and C.D. Marsden Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors Biochem. Pharmacol. 32 1983 2921 2927 (Pubitemid 13013728)
22. R.A. Floyd Role of oxygen free radicals in carcinogenesis and brain ischemia FASEB J. 4 1990 2587 2597
23. R.R. Gainetdinov, T.V. Grekhova, T.D. Sotnikova, and K.S. Rayevsky Dopamine D-2 and D-3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats Eur. J. Pharmacol. 261 1994 327 331
24. W.F. Gattaz, A. Emrich, and S. Behrens Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia J. Neural Transm. Gen. Sect. 92 1993 197 201 (Pubitemid 23210662)
25. W.M. Glazer, H. Morgenstern, and J.T. Doucette Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications J. Clin. Psychiatry 54 1993 133 139 (Pubitemid 23141515)
26. B. Halliwell Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97 2006 1634 1658 (Pubitemid 43873658)
27. E.H. Hamid, T.M. Hyde, S.M. Baca, and M.F. Egan Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia Brain Res. 796 1998 291 295 (Pubitemid 28343259)
28. E. Hangen, K. Blomgren, P. Benit, G. Kroemer, and N. Modjtahedi Life with or without AIF Trends Biochem. Sci. 35 2010 278 287
29. K. Iwahashi, K. Anemo, K. Nakamura, I. Fukunishi, and K. Igarashi Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism Neuropsychobiology 44 2001 126 128 (Pubitemid 34701618)
30. N. Joza, J.A. Pospisilik, E. Hangen, T. Hanada, N. Modjtahedi, J.M. Penninger, and G. Kroemer AIF: not just an apoptosis-inducing factor Natural Compounds and Their Role in Apoptotic Cell Signaling Pathways 1171 2009 2 11
31. J.M. Kane, M. Woerner, J.A. Lieberman, P. Weinhold, W. Florio, M. Rubinstein, J. Rotrosen, J. Kurucz, S. Mukherjee, K. Bergmann, and N.R. Schooler The prevalence of tardive-dyskinesia Psychopharmacol. Bull. 21 1985 136 139
32. M.B. Knable, T.M. Hyde, M.F. Egan, M. Tosayali, R.J. Wyatt, and J.E. Kleinman Quantitative autoradiography of striatal dopamine D1, D2 and re-uptake sites in rats with vacuous chewing movements Brain Res. 646 1994 217 222 (Pubitemid 24151755)
33. Y. Kono Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase Arch. Biochem. Biophys. 186 1978 189 195 (Pubitemid 8290500)
34. Y. Kotake Pharmacologic properties of phenyl N-tert-butylnitrone Antioxid. Redox Signal. 1 1999 481 499 (Pubitemid 129628311)
35. S.K. Kulkarni, M.K. Bhutani, and M. Bishnoi Antidepressant activity of curcumin: involvement of serotonin and dopamine system Psychopharmacology (Berl) 201 2008 435 442
36. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
37. G.J. LaHoste, J. Yu, and J.F. Marshall Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity Proc. Natl. Acad. Sci. U.S.A. 90 1993 7451 7455 (Pubitemid 23249967)
38. E. Lancelot, M.L. Revaud, R.G. Boulu, M. Plotkine, and J. Callebert alpha-Phenyl-N-tert-butylnitrone attenuates excitotoxicity in rat striatum by preventing hydroxyl radical accumulation, Free Radic Biol. Med. 23 1997 1031 1034 (Pubitemid 27451290)
39. P. Lerner, P. Nose, E.K. Gordon, and W. Lovenberg Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover Science 197 1977 181 183 (Pubitemid 8140044)
40. M. Marsalek Tardive drug-induced extrapyramidal syndromes Pharmacopsychiatry 33 Suppl 1 2000 14 33
41. B.E. Mileson, and R.D. Schwartz The use of locomotor-activity as a behavioral screen for neuronal damage following transient forebrain ischemia in gerbils Neurosci. Lett. 128 1991 71 76
42. W.G. Niehaus Jr., and B. Samuelsson Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation Eur. J. Biochem. 6 1968 126 130
43. E. Obuchowicz, R. Krysiak, J.M. Wieronska, M. Smialowska, and Z.S. Herman Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity Neuropeptides 39 2005 515 523 (Pubitemid 41444260)
44. C.N. Oliver, P.E. Starke-Reed, E.R. Stadtman, G.J. Liu, J.M. Carney, and R.A. Floyd Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion- induced injury to gerbil brain Proc. Natl. Acad. Sci. U.S.A. 87 1990 5144 5147
45. H. Qing, H. Xu, Z. Wei, K. Gibson, and X.M. Li The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis Eur. J. Neurosci. 17 2003 1563 1570 (Pubitemid 36628125)
46. R.M. Rogoza, D.F. Fairfax, P. Henry, S. Marandi, R.F. Khan, S.K. Gupta, and R.K. Mishra Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia Synapse 54 2004 156 163 (Pubitemid 39435345)
47. J.D. Salamone, A.J. Mayorga, J.T. Trevitt, M.S. Cousins, A. Conlan, and A. Nawab Tremulous jaw movements in rats: a model of parkinsonian tremor Prog. Neurobiol. 56 1998 591 611 (Pubitemid 29012460)
48. P. Seeman Brain dopamine receptors Pharmacol. Rev. 32 1980 229 313
49. P. Seeman Antipsychotic drugs, dopamine receptors, and schizophrenia Clin. Neurosci. Res. 1 2001 53 60 (Pubitemid 33713784)
50. P. Seeman Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High) Schizophr. Res. 109 2009 191 192
51. P. Seeman All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 receptors CNS Neurosci. Ther. 17 2010 118 132
52. S. Sharma, P. Paladino, J. Gabriele, H. Saeedi, P. Henry, M. Chang, R.K. Mishra, and R.L. Johnson Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: a model of human tardive dyskinesia Peptides 24 2003 313 319 (Pubitemid 36369353)
53. K.J. Skoblenick, J.M. Castellano, R.M. Rogoza, B.A. Dyck, N. Thomas, J.P. Gabriele, V.Z. Chong, and R.K. Mishra Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment Apoptosis 11 2006 663 672 (Pubitemid 43876837)
54. Y.K. Skrobik, N. Bergeron, M. Dumont, and S.B. Gottfried Olanzapine vs haloperidol: treating delirium in a critical care setting Intensive Care Med. 30 2004 444 449 (Pubitemid 38375619)
55. C. Sookram, M. Tan, R. Daya, S. Heffernan, and R.K. Mishra Curcumin prevents haloperidol-induced development of abnormal oro-facial movements: possible implications of Bcl-XL in its mechanism of action Synapse 65 8 2011 788 794
56. H. Takeuchi, J. Ishigooka, K. Kobayashi, S. Watanabe, and S. Miura Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs Prog. Neuropsychopharmacol. Biol. Psychiatry 22 1998 679 691 (Pubitemid 28281230)
57. G. Tsai, D.C. Goff, R.W. Chang, J. Flood, L. Baer, and J.T. Coyle Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia Am. J. Psychiatry 155 1998 1207 1213 (Pubitemid 28402514)
58. P. Turrone, G. Remington, and J.N. Nobrega The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci. Biobehav. Rev. 26 2002 361 380 (Pubitemid 34553319)
59. D. Wang, and D. Corbett Cerebral-ischemia, locomotor-activity and spatial-mapping Brain Res. 533 1990 78 82
60. M.G. Woerner, J.M.J. Alvir, B.L. Saltz, J.A. Lieberman, and J.M. Kane Prospective study of tardive dyskinesia in the elderly: rates and risk factors Am. J. Psychiatry 155 1998 1521 1528 (Pubitemid 28512019)
61. S. Wolfarth, and K. Ossowska Can the supersensitivity of rodents to dopamine be regarded as a model of tardive dyskinesia? Prog. Neuropsychopharmacol. Biol. Psychiatry 13 1989 799 840 (Pubitemid 19238694)
62. A.M. Wright, J. Bempong, M.L. Kirby, R.L. Barlow, and J.R. Bloomquist Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia Brain Res. 788 1998 215 222 (Pubitemid 28202164)